As teams lock in Q4 budgets and head into RSNA season, the FDA’s AI lifecycle draft (Jan 2025) and the now-final PCCP (Dec 2024) have reset what buyers should expect from AI in imaging—devices, software, and workflows. Vendors are updating claims and governance; this issue distills a practical buyer’s checklist—multisite validation with subgroup results, drift monitoring and version control, clear in-viewer transparency—and how pairing those tools with Vesta’s subspecialty coverage and QA turns promise into measurable gains across CT/MRI/US/mammography.

A practical buyer’s checklist

Use this when evaluating AI for your service lines:

1. Intended use fit: Verify indications, inputs/outputs, and claims match your pathway and patient mix.
2. Validation depth: Prefer multisite, diverse datasets; stratified results; pre-specified endpoints; documented data lineage and splits.
3. Bias mitigation: Demand subgroup performance (sex, age, race/ethnicity when available), scanner/vendor variability analyses, and site-transfer testing.
4. TPLC plan: Require drift monitoring, retraining triggers, versioning, and how updates are communicated.
5. Human factors & transparency: Ensure limitations, failure modes, and interpretable outputs are presented in-viewer without slowing reads.
6. Security & support: Patch cadence, vulnerability disclosure, SOC2/ISO posture, uptime SLAs, and rollback paths for version issues.
7. Governance: Define metrics owners, review cadence, and thresholds to pause or roll back a model.

Implementation playbook: pilot → scale without disruption

Start with a 60–90 day pilot in one high-impact line (e.g., ED stroke CT or mammography triage) and lock in baselines: median TAT, positive/negative agreement, recall rate, PPV/NPV, and discrepancy rate. Set guardrails—when to auto-triage vs. force human review—and document escalation paths for model failures. Require case-level confidence and structured outputs your radiologists can verify quickly. Stand up a model governance huddle (modality lead, QA, IT security, and your teleradiology partner) that meets biweekly to review drift signals, subgroup performance, and near-misses. Bake in a rollback plan (version pinning) and a quiet-hours change window so updates don’t collide with peak volumes. As results stabilize, scale by cohort (e.g., expand to non-contrast head CT, then CTA) and keep training “micro-bursts” for techs/readers—short videos or checklists in-workflow. Tie vendor SLAs to uptime, support response, and clinical KPIs so the AI program stays accountable to operational value.

Where teleradiology fits

AI only delivers when it’s welded to coverage, quality, and speed. A teleradiology partner should provide:

• 24/7 subspecialty + surge capacity: Vesta absorbs volume peaks so AI never becomes a bottleneck.
• QA you can see: We benchmark pre/post-AI performance, add targeted second looks for edge cases, and feed variance data back to your team.
• Standardized outputs: Structured reports that integrate model outputs with radiologist findings—no black-box surprises.
• Smooth rollout: Pilot by service line (stroke CT, mammo triage, PE workups), then scale with tracked KPIs (TAT, PPV, recalls).
• Interoperability & security: Seamless PACS/RIS/EMR integration with strict access controls, audit trails, and support for change-controlled updates.

Bottom line: Pairing AI with Vesta Teleradiology gives you round-the-clock subspecialty reads, measurable QA, and operational breathing room while you pilot and scale responsibly. If you’re mapping your AI roadmap under the FDA’s 2025 draft guidance, we’ll be your coverage and quality backbone—so your clinicians see faster answers and your patients see safer care. Visit vestarad.com to get started.

The post FDA’s 2025 AI Draft Guidance: A Buyer’s Checklist for Imaging Leaders first appeared on Vesta Teleradiology.

Key Updates in MRI Standards

Remote Scanning Protocols: The revised standards mandate that a registered technologist must always be present with the patient during remote MRI scans. This ensures immediate care availability if needed. Facilities are also required to implement policies addressing potential challenges such as equipment or communication failures, internet instability, and power outages.

Portable MRI Scanning: The IAC has introduced standards for portable MRI technology, distinguishing it from mobile MRI units. This inclusion acknowledges the growing use of portable MRI devices in various healthcare settings and emphasizes the need for specific guidelines to ensure their safe and effective operation.

Contrast Administration and Supervision: Recognizing the challenges in meeting physician supervision requirements for contrast injections, the IAC has revised its policies to ensure a safe environment for patients. The new standards emphasize the presence of appropriately trained nonphysician personnel during contrast administration.

Implications for Healthcare Providers

These updates reflect the IAC’s commitment to quality improvement and patient safety in MRI services. Facilities must comply with the new standards to maintain accreditation, which may involve updating protocols, training staff, and investing in new technologies. The emphasis on remote scanning and portable MRI acknowledges the evolving landscape of medical imaging and the need for standards that keep pace with technological advancements.

Industry Response

The introduction of these standards has been met with support from industry stakeholders. For instance, Hyperfine, a manufacturer of portable MRI devices, noted that the new guidelines pave the way for their Swoop® Portable MR Imaging® system to be available in neurology offices and clinics. This development enables physicians to obtain diagnostic-quality MR brain images within their clinics, providing patients with timely and convenient MRI access at the point of care.

Conclusion

The CMS-approved MRI standards introduced by the IAC represent a significant step forward in ensuring patient safety and adapting to technological advancements in medical imaging. Healthcare providers are encouraged to familiarize themselves with these updates and implement the necessary changes to comply with the new accreditation requirements. As the medical imaging landscape continues to evolve, such proactive measures are essential to maintain high standards of care and patient safety.

Sources:
radiologybusiness.com
auntminnie.com
openai.com

The post New CMS-Approved MRI Standards: Enhancing Safety in Remote Scanning and Portable Imaging first appeared on Vesta Teleradiology.

The Magnetom Terra.X: MRI System

The Magnetom Terra.X, a new 7T MRI system, has received 510(k) clearance from the FDA. Manufactured by Siemens Healthineers, it’s a second-generation successor to the Magnetom Terra and offers several enhancements for 7T imaging. Key features include an eight-channel parallel transmit architecture for clinical use, deep learning image reconstruction optimized for 7T, improved diffusion imaging with a high-performance gradient system, and accelerated image acquisition enabling high-resolution brain and knee exams in under 20 minutes. Siemens Healthineers sees this as a significant step in providing better patient care, particularly in neurological and knee imaging. Additionally, the FDA clearance allows existing Magnetom Terra systems to be upgraded to the Magnetom Terra.X.

SyMRI 3D for Brain Imaging

SyntheticMR has announced that its latest imaging solution, SyMRI 3D, has received FDA 510(k) clearance for clinical use in the United States. This clearance marks a significant advancement in quantitative MRI technology, offering exceptional resolution and accuracy in brain imaging. SyMRI 3D enables precise volumetric estimations of brain regions, known as parcellation, providing clinicians with deeper insights into brain structure and function. The enhanced resolution facilitates comprehensive lesion analysis, leading to more accurate medical condition assessments. This clearance empowers physicians to make more informed decisions in diagnosis and treatment planning, ultimately improving patient outcomes. SyntheticMR reaffirms its dedication to advancing medical imaging technology and providing innovative tools to enhance patient care through this milestone.

nCommand Lite for Remote Scanning

GE Healthcare has highlighted the FDA clearance of a solution by Ionic Health that enables technologists to remotely supervise patient scans. The system, called “nCommand Lite,” has been tested in Brazil for three years and is vendor-agnostic, allowing remote supervision across MRI, CT, and PET modalities. GE has secured exclusive distribution rights for nCommand in the U.S., aiming to address ongoing workforce shortages in healthcare. Rekha Ranganathan, GE’s chief digital officer for imaging, emphasized the company’s commitment to remote operations and increasing patient access to expert technologists. The system facilitates not only scanning supervision but also training, procedure assessment, and scanning parameter management. GE’s announcement coincides with growing interest in remote scanning, with the American College of Radiology advocating for permanent remote supervision of diagnostic tests. However, technologists have expressed reservations about managing imaging remotely, according to recent survey data from the American Society of Radiologic Technologists.

Sources:

Itnonline.com
Radiologybusiness.com
diagnosticimaging.com
openai.com

The post New FDA Clearances for Imaging Systems and Solutions first appeared on Vesta Teleradiology.

AI-based Quantitative Brain Imaging System

Philips and Synthetic MR have joined forces to advance the diagnosis of neurological disorders through cutting-edge quantitative brain imaging tools. Their collaboration introduces the Smart Quant Neuro 3D MRI software suite, combining Philips’ SmartSpeed image-reconstruction technology, the 3D SyntAc clinical application, and SyntheticMR’s SyMRI NEURO 3D software. This innovation employs AI to analyze brain tissues, enhancing the detection and analysis of conditions like multiple sclerosis, traumatic brain injuries, and dementia.

The rise of AI in diagnostic imaging, projected to reach $1.2bn by 2027, signifies a transformative shift in improving accuracy and patient outcomes. With the diagnostic imaging market expected to grow to $9.1bn by 2030, fueled by demand for early disease diagnosis and personalized medicine, this partnership underscores the crucial role of AI in enhancing medical imaging.

Read the press release here.

A New Way of Diagnosing Mild TBIs

Researchers have developed a novel brain imaging method to diagnose mild traumatic brain injuries (mTBIs), which are often missed by standard techniques like MRI. This method involves loading gadolinium, a common MRI contrast agent, into micropatches attached to immune cells called macrophages. These cells migrate to areas of brain inflammation caused by mTBIs, enabling MRI detection. The technique, called M-GLAMs, was successfully tested in mice and pigs, showing promise for accurately diagnosing mTBIs. It also allows imaging at lower gadolinium doses, potentially benefiting patients with kidney issues. While unable to pinpoint injury locations, M-GLAMs could aid in identifying and treating brain inflammation. The researchers aim to bring this technology to clinical trials, with support from grants and intellectual property protection.

Read the study here.

New Imaging Tech that Captures Neuronal Activity Across the Brain During Recovery

Researchers at Tufts University School of Medicine have developed a novel imaging technology to monitor neuronal activity throughout the entire brain during the initial weeks of recovery from traumatic brain injury (TBI). Their study, published in Cerebral Cortex, reveals that TBI can induce changes in brain function beyond the injury site. Using a combination of fluorescent sensors and electrodes, they observed altered connectivity patterns in mice post-injury, even in regions distant from the impact. Despite the mice’s ability to perform physical tasks normally, their brain activity during both exercise and rest differed significantly from healthy brains. This impaired ability to switch between states suggests underlying brain state dysfunction post-injury. The findings highlight the brain’s plasticity in response to injury and have potential clinical implications for understanding TBI impacts and tailoring treatments. The researchers aim to further investigate long-term neural activity changes post-recovery and explore the technology’s potential in predicting specific dysfunctions or long-term outcomes of TBI. 

Read the study here.

Sources:

Medicaldevice-network.com
Otd.harvard.edu
Scitechdaily.com
Openai.com

The post The Latest in Brain Imaging News first appeared on Vesta Teleradiology.

July is Bone Cancer and Sarcoma Awareness Month. According to the American Association for Cancer Research, in 2021, around 13,000 Americans will be diagnosed with soft tissue sarcoma, while 3,600 will be diagnosed with bone cancer. Luckily, the 5-year survival rate of both types of cancer is fairly high (65 for soft tissue and 66.8 for bone). In a comprehensive study from 1978 to 2004, the survival rate of these types of cancers has improved dramatically, thanks in part to improvements in imaging and early detection.

Advances in Radiography

While x-ray technology has been used in a health context since 1899, many features surrounding it have changed. X-rays are now more defined with higher resolution, allowing doctors to zoom in to see smaller tumors and other issues. In fact, this past year, scientists at the University of Erlangen-Nuremberg have broken the record for x-ray resolution, down to under 10 nanometers. Furthermore, the process of obtaining can now be digitized, rather than having to use a darkroom to develop scans. These developments make radiology more accessible to patients and provide more immediate results, which helps bone cancer and sarcoma patients get diagnosed earlier when time is of the essence. There are multiple types of radiography used in diagnosing these types of cancer, and specific advances have emerged and evolved the diagnostic process for each type.

 

Bone Scans

During bone scans, a patient is injected with a tracer that allows oncologists to see abnormalities. Recent changes in bone scans allow doctors to quantify the metastasis of a bone from a scan. Bone scans can sometimes occur as a diagnostic tool before a CT scan, PET scan, or MRI.

 

CT Scans

CT scans can be ordered with “contrast,” where the patient swallows or takes an IV containing a dye. This can help doctors see certain organs more clearly. These scans can also help doctors see a cross-section of parts of the body and different perspectives of organs than they’d be able to see with a typical x-ray. The latest advancements in CT scans now offerlower radiation exposure by splitting the x-ray beams, making these procedures safer than ever.

 

PET Scans 

Positron emission tomography (PET) imaging is an emerging tool for bone cancer patients receiving radiation treatments. This tool is now being used increasingly by doctors to monitor tumors between treatments. These advanced scans allow more doctors to receive more information, including receptor expression and metabolism of a tumor. This information helps doctors to understand whether or not a particular type of treatment is working to shrink tumors and to help assess the appropriate dosage.

 

MRI Scans

Magnetic resonance imaging or MRI scans help oncologists to see the extent of bone and soft tissue cancers by taking cross-sections of affected organs and allowing them to be displayed at different angles. These are taken around a patient while a patient lies still inside a long tube. The most recent changes in MRI technologyhave occurred on the software side. One relevant change includes faster scan times, thereby reducing costs and discomfort for the patient. Furthermore, multiple layers of contrast can now be taken from a single scan, allowing doctors to highlight different issues easily.

While bone and soft tissue cancers affect many Americans, advancement in imaging tools helps provide clarity and hope for these patients.

Tech Innovation in Teleradiology

Vesta Teleradiology prides itself in being a top innovator in technology and was even awarded this recognition in 2020 by Technology Innovators. We truly understand the importance of keeping up with medical and technological advancements in radiology, imaging and health.

 

Come to us for teleradiology services for your outpatient imaging centers, nursing homes, hospitals, mobile imaging, wellness centers and urgent care facilities. Expect flexible yet speedy service, with quality interpretations and customizable reports. Please contact us for a quote.

The post Sarcoma & Bone Cancer Awareness Month: Newest Technology in Imaging first appeared on Vesta Teleradiology.